Tinnitus

Tinnitus is the perception of sound in the absence of any external stimulus — patients describe it as ringing, hissing, whistling, humming, buzzing, chirping, or clicking.^[1] It is genuinely common: an estimated 41% of people aged 3 to 79 will experience tinnitus at least once in their lifetimes, most often older adults, and roughly 1 in 5 patients who experience it report it as genuinely bothersome — associated with decreased sleep, impaired concentration, or a worsened mood.^[1] That bothersome/nonbothersome distinction matters clinically: most people with tinnitus need only reassurance, while a bothersome, persistent presentation is where the evidence-based therapies in this chapter (see Non-Pharmacologic Treatment) genuinely change quality of life.

Two classification questions structure essentially the entire diagnostic approach and are worth asking, explicitly, in every patient. The first is pulsatile versus nonpulsatile: nonpulsatile tinnitus is by far the more common presentation, is typically subjective (heard only by the patient), and is usually related to hearing loss of some kind; pulsatile tinnitus is often heartbeat-synchronous, can sometimes be objective (audible to an examiner on auscultation), and — unlike routine subjective tinnitus — specifically warrants a vascular and structural imaging workup, since its differential includes a dural arteriovenous fistula, arteriovenous malformation, carotid pathology, a glomus tumour, or a venous sinus abnormality (see Recognize the Condition and Red Flags & Refer).^[1][2] The second is unilateral versus bilateral: bilateral, symmetric tinnitus is the pattern most consistent with routine age-related or noise-related hearing loss, while unilateral tinnitus — or tinnitus accompanied by asymmetric hearing loss — is a red flag warranting audiology referral and imaging to exclude a vestibular schwannoma, exactly as in the Hearing Loss chapter's own asymmetric-hearing-loss red flag.^[1]

This chapter also gives genuine centerpiece weight to drug-induced ototoxicity, because tinnitus itself — not a change on formal audiometry — is very often the earliest, most practical, patient-reportable warning sign that an ototoxic drug is causing harm, sometimes appearing before any measurable hearing threshold shift.^[3] See Risk Factors and Drug Tables for a genuinely detailed, agent-by-agent breakdown. Finally, this chapter states plainly, rather than glossing over, an honest and important expectation-setting point: for most patients with chronic tinnitus (symptoms lasting more than 6 months), there is no cure, because the underlying cause is typically hearing loss that is itself not reversible — the goal of management is not eliminating the sound, but reducing its impact on the patient's life through evidence-based non-pharmacologic therapy, amplification where indicated, and active management of any comorbid anxiety, depression, or sleep disturbance.^[1] This chapter is deliberately scoped to tinnitus itself; for the full ototoxicity-monitoring protocol and sudden sensorineural hearing loss, see the Hearing Loss chapter, and for the specific endolymphatic-hydrops tetrad of episodic vertigo, fluctuating hearing loss, tinnitus, and aural fullness, see the Ménière's Disease chapter.

Subjective (nonpulsatile) tinnitus — the common presentation

Subjective tinnitus is only heard by the patient and accounts for the large majority of presentations. It is typically related to some form of hearing loss — most often age-related presbycusis or noise-induced hearing loss, both usually gradual and bilateral, but also, importantly for this chapter, drug-induced ototoxicity (see Risk Factors and Drug Tables).^[1] Bilateral, symmetric subjective tinnitus without other red-flag features is the pattern most consistent with routine hearing loss and generally does not require imaging.^[2] Unilateral subjective tinnitus, even without a pulsatile quality, is treated differently — see Red Flags & Refer.

Objective (pulsatile) tinnitus — often heartbeat-synchronous, sometimes audible to an examiner

Pulsatile tinnitus is a distinct subtype, representing roughly 5-10% of all tinnitus presentations, characterized by a perception of heartbeat-synchronous sound; it is often, though not always, objective — capable of being heard by an examiner on auscultation.^[2] Within pulsatile tinnitus, a further distinction matters: pulse-synchronous tinnitus (typically vascular in origin) versus pulse-asynchronous, or "pseudo-pulsatile," tinnitus caused by palatal muscle contraction or tensor tympani/stapedius muscle spasm (myoclonus) rather than a vascular source.^[1][2] This distinction is genuinely important because pulse-synchronous pulsatile tinnitus specifically warrants a vascular and structural imaging workup that routine subjective tinnitus does not (see Red Flags & Refer and Assessment & Diagnosis).

Natural history — set honest expectations early

General risk factors

• Age — prevalence rises with age, peaking in the 60- to 69-year age range.^[1]
• Obesity (BMI ≥30 kg/m²), smoking, diabetes mellitus, and hypertension — all recognized associated risk factors.^[1]
• Noise exposure, occupational or recreational, and prior acoustic trauma — cross-reference the Hearing Loss chapter's prevention content (the 80-to-90 rule and hearing protection are covered in Non-Pharmacologic Treatment below).
• Pre-existing or comorbid hearing loss of any cause — the single most common underlying driver of subjective tinnitus.
• Mood disorders — anxiety and depression both worsen the perceived severity and quality-of-life impact of tinnitus, and the relationship runs in both directions (see Special Populations and Monitoring & Follow-Up).

Ototoxic-drug risk factors — the pharmacist-critical core of this chapter

Tinnitus is very often the earliest clinical sign of drug-induced ototoxicity — frequently appearing before any change is detectable on formal audiometry — which makes it a genuinely practical, low-cost, patient-reportable warning sign that a pharmacist is well positioned to ask about at every relevant contact.^[3] As in the Hearing Loss chapter, ototoxicity severity is generally dose-dependent and cumulative, and is influenced by age, renal or cardiac comorbidity, genetic susceptibility, route, duration of therapy, and pre-existing hearing loss.^[3] The scale of this problem is genuinely broad: a 2020 comprehensive review catalogued 194 systemically administered medications with evidence of cochleotoxicity, vestibulotoxicity, or dizziness — most commonly antimicrobials, psychotropics, antihypertensives/antiarrhythmics, NSAIDs, and antineoplastics — with tinnitus a frequently reported presenting symptom well beyond the individual agents detailed below.^[4]

History

Direct the history at the 2 classification questions that drive the entire work-up: is the tinnitus pulsatile or nonpulsatile, and is it unilateral or bilateral? Also establish whether it is bothersome or nonbothersome, whether hearing loss, vertigo, or other neurologic symptoms accompany it, and — genuinely central to this chapter — take a complete history of past or current ototoxic medication use, along with any history of acoustic trauma or occupational noise exposure.^[1] This medication-focused history is one of the most valuable contributions a pharmacist can make to the diagnostic picture.

Physical examination

Perform a cranial nerve examination and otoscopy in every patient.^[1] For patients with pulsatile tinnitus specifically, auscultate over the neck, mastoid, and preauricular areas for bruits, and extend auscultation to the orbital and temporal/retroauricular regions when an arteriovenous fistula is suspected.^[1][2] A jugular venous compression test is a genuinely useful bedside maneuver in pulsatile tinnitus: venous pulsatile tinnitus tends to be low-pitched and often improves or disappears with gentle compression of the ipsilateral jugular vein, while tinnitus that worsens with compression, or does not change, points instead toward an arterial source.^[2] A positive compression response supports, but does not by itself confirm, a benign venous hum — vascular imaging is still reasonable given how broad the differential remains (see below).

Audiologic evaluation

All patients with tinnitus should be referred to an audiologist for a formal audiologic evaluation, to establish auditory function and identify any hearing loss.^[1] A comprehensive tinnitus assessment characterizes 4 parameters: pitch, loudness, maskability, and residual inhibition.^[1] A validated instrument such as the Tinnitus Handicap Inventory is a genuinely useful adjunct to quantify the functional and quality-of-life impact at baseline and at follow-up, particularly for bothersome tinnitus (see Monitoring & Follow-Up).^[3]

Imaging — targeted by tinnitus subtype, not routine

Differential diagnosis

• Correctly classify tinnitus as pulsatile versus nonpulsatile and unilateral versus bilateral at the first encounter, since this classification — not the tinnitus itself — is what drives the entire subsequent work-up.
• Identify and refer pulsatile tinnitus for a genuine vascular/structural work-up, and unilateral tinnitus or tinnitus with asymmetric hearing loss for audiology and imaging to exclude a vestibular schwannoma, rather than defaulting either presentation to routine reassurance.
• Identify and address any treatable underlying cause — cerumen impaction, a structural vascular lesion, or an ototoxic medication — wherever one genuinely exists.
• For ototoxic drug-induced tinnitus specifically: recognize it as an early, often still-modifiable warning sign and coordinate with the prescriber on dose adjustment, interval change, agent substitution, or discontinuation, weighed explicitly against the necessity of the causative therapy.
• Set honest, accurate expectations for chronic subjective tinnitus — there is no cure for most patients, and the goal is reducing impact, not eliminating the sound.
• Reduce the bother and quality-of-life impact of persistent tinnitus through the non-pharmacologic therapies with genuine efficacy data — cognitive behavioral therapy, sound therapy, and tinnitus retraining therapy — rather than reaching for unproven or explicitly not-recommended pharmacotherapy.
• Support hearing aid evaluation and amplification for any patient with comorbid hearing loss.
• Screen for and actively address comorbid anxiety, depression, and sleep disturbance as a genuine, important component of care in bothersome tinnitus, not an afterthought.

Chronic subjective (nonpulsatile) tinnitus

Every patient set honest expectations: for chronic tinnitus (>6 months), there is no cure in most cases, and management is about reducing impact, not eliminating the sound.^[1] Identify and treat any genuinely reversible contributing cause (cerumen impaction, an ototoxic medication — see below) before assuming none exists. Nonbothersome reassurance and conservative measures (sound therapy basics, hearing protection) are usually sufficient — see Non-Pharmacologic Treatment.^[1] Persistent and bothersome refer for a hearing aid evaluation if hearing loss is present, and recommend cognitive behavioral therapy — genuinely evidence-supported and currently recommended for persistent, bothersome tinnitus.^[8][1] Sound therapy and tinnitus retraining therapy are reasonable adjuncts, though the trial evidence supporting sound therapy specifically is graded at the "option" level rather than a full recommendation — disclose this honestly rather than overstating it.^[8]

What current guidance explicitly advises against for primary tinnitus

Do not routinely recommend antidepressants, anticonvulsants, or anxiolytics for a primary indication of treating persistent, bothersome tinnitus — current guidance recommends against this specifically.^[8] Do not routinely recommend intratympanic medications for primary tinnitus, and do not recommend ginkgo biloba, zinc, or other dietary supplements as a tinnitus treatment.^[8] A genuine, worth-disclosing tension exists specifically around melatonin: the Canadian review notes exogenous melatonin has shown symptom improvement, particularly for tinnitus-associated sleep disturbance, while the AAO-HNSF guideline's "recommendation against" for dietary supplements is not agent-specific and would technically include it — the honest position is that melatonin is reasonable as a sleep-focused adjunct in a patient with tinnitus-related insomnia, not as a therapy marketed to "treat the tinnitus" itself.^[1][8] Separately, when a patient has a formally diagnosed comorbid depression or anxiety disorder alongside their tinnitus, a tricyclic antidepressant or selective serotonin reuptake inhibitor is a reasonable choice for that diagnosed comorbidity on its own merits — this is treating the depression or anxiety, not the tinnitus itself, and the distinction is worth explaining clearly to the patient.^[1][8]

Ototoxic drug-induced tinnitus — the pharmacist's core decision

New or worsening tinnitus reported during a course of a known ototoxic agent escalate to the prescriber promptly — this is genuinely one of the most actionable findings in this entire chapter, since tinnitus frequently precedes a measurable audiometric change.^[3] The decision is a genuine risk-benefit discussion (dose reduction, longer interval, agent switch, or discontinuation, weighed against the necessity of the causative therapy), not automatic discontinuation — see the Hearing Loss chapter's Choose Initial Treatment and Monitoring & Follow-Up for the full protocol, which this chapter deliberately does not duplicate.

Pulsatile tinnitus with an identified structural or vascular cause

Management (embolization or resection of a dural arteriovenous fistula or malformation, surgical management of a glomus tumour, venous sinus stenting for idiopathic intracranial hypertension-related stenosis, or carotid intervention where indicated) is directed by neurotology, neurosurgery, or interventional neuroradiology once a structural cause is identified — not a pharmacist decision, but relevant to counseling a patient about what to expect from referral.

Cognitive behavioral therapy — the best-supported therapy for bothersome tinnitus

Recommended CBT aims to correct a patient's negative emotional and behavioral response to tinnitus, primarily through counseling and relaxation techniques, rather than attempting to eliminate the perception of sound itself.^[1] It has been shown to improve quality of life and decrease depression in tinnitus sufferers and is currently recommended for persistent and bothersome tinnitus.^[1][8]

Sound therapy and masking

• Hearing aids — for a patient with comorbid hearing loss, hearing aids serve a dual role: restoring audibility (see the Hearing Loss chapter for the full amplification discussion) and acting as a masker by introducing ambient sound that reduces the perceived prominence of tinnitus.^[1] Current guidance recommends a hearing aid evaluation for any patient with hearing loss and persistent, bothersome tinnitus.^[8]
• Dedicated tinnitus maskers and white-noise generators — adjustable nature sounds or broadband noise devices have been shown to decrease perceived tinnitus severity and improve sleep.^[1]
• Tinnitus retraining therapy (TRT) — combines directive counseling with ear-level noise generators to help dissociate the tinnitus percept from the patient's negative emotional response to it, distinct from CBT's more purely psychological approach.^[1]

Prevention

• The 80-to-90 rule — a genuinely practical, patient-facing primary prevention target: keep personal listening device volume at 80% of maximum, and limit listening to under 90 minutes per day.^[1]
• Occlusive headphones reduce the need to raise volume to overcome external noise, which itself lessens delivered sound intensity.^[1]
• Noise protection more broadly during and after any planned ototoxic drug course — cross-reference the Hearing Loss chapter's specific counseling on avoiding loud noise exposure during, and for several months after, a course of a known ototoxic agent.
• Dietary factors — reducing carbohydrate and cholesterol intake has been proposed as a way to help prevent age-related hearing loss, though this is a softer, adjunctive recommendation rather than a primary intervention.^[1]

Lifestyle and conservative measures

• Improving sleep hygiene, reducing stress, and reducing caffeine and alcohol consumption are reasonable, low-risk conservative measures for any patient with tinnitus, bothersome or not.^[1]
• For patients with genuinely nonbothersome tinnitus, reassurance plus these conservative measures is usually sufficient — avoid over-medicalizing a presentation that does not need aggressive intervention.

What is investigational, not yet standard of care

Transcranial magnetic stimulation has been proposed as a noninvasive treatment for chronic bothersome tinnitus, but it remains available only within research trials and should not be presented to patients as an established, accessible therapy.^[1]

Surgical management — rare, and only for a specific treatable cause

Surgery is very rarely used for tinnitus itself, and only when a specific treatable underlying cause is identified: acoustic neuroma resection, endolymphatic sac shunting for Ménière's disease (see the dedicated chapter), stapedectomy for otosclerosis, or tensor tympani/stapedius muscle sectioning for muscular myoclonus.^[1] For pulsatile tinnitus with an identified vascular lesion, see Choose Initial Treatment.

Pediatrics

Tinnitus is uncommonly the presenting complaint in children, but the ototoxic-drug risk factors in this chapter remain directly relevant — aminoglycoside courses in neonatal intensive care and cisplatin in pediatric oncology both carry real, and in the case of cisplatin materially higher, ototoxicity risk in young children; see the Hearing Loss chapter's Special Populations for the full pediatric monitoring discussion. When a child does report new tinnitus, take the same history-driven approach (pulsatile versus nonpulsatile, unilateral versus bilateral, ototoxic medication history) rather than assuming it is benign because tinnitus is rare in this age group.

Pregnancy and breastfeeding

Most tinnitus assessment and non-pharmacologic management (reassurance, sound therapy, CBT) is safe and appropriate in pregnancy and breastfeeding. Defer non-urgent imaging where clinically reasonable, and coordinate any genuinely indicated imaging with obstetrics. Aminoglycosides, high-dose salicylates, and cisplatin each carry their own separate pregnancy-specific risk considerations beyond ototoxicity and should be managed by the treating specialist with those in mind; confirm any medication decision against the specific drug's own Drug Database entry.

Older adults

Age is one of the strongest risk factors for tinnitus, and presbycusis raises baseline hearing loss while narrowing the detectable margin before a new ototoxic effect becomes clinically apparent — making a baseline hearing/tinnitus check more valuable, not less, before a planned ototoxic course in this group (see the Hearing Loss chapter). Polypharmacy also raises the real possibility of cumulative or stacked ototoxic exposure — for example, chronic NSAID or high-dose ASA use layered onto an acute aminoglycoside or macrolide course — making a targeted medication review a genuinely useful pharmacist contribution. Comorbid depression and social isolation are also more prevalent in this group and compound the quality-of-life impact of bothersome tinnitus (see below).

Comorbid anxiety, depression, and sleep disturbance — a real, important part of management

When tinnitus is severe enough to significantly affect quality of life, actively screen for and address comorbid anxiety, depression, and sleep disturbance rather than treating them as separate from tinnitus management.^[1] Increasing tinnitus severity is inversely associated with quality of life, and mood disorders are among the factors most consistently shown to affect a patient's expected outcome and functional impact.^[1] CBT itself has documented benefit for comorbid depression in tinnitus sufferers, and a formally diagnosed comorbid depression or anxiety disorder is a genuine, appropriate indication for a tricyclic antidepressant or SSRI on its own merits (see Choose Initial Treatment) — distinct from, and not to be confused with, using an antidepressant as an unproven attempt to treat the tinnitus percept itself.^[1] For any patient expressing hopelessness or suicidal ideation in the context of severe, distressing tinnitus, escalate urgently per the Suicide Risk & Prevention chapter rather than assuming this will resolve with routine reassurance.

Occupational and recreational noise exposure

Patients with significant occupational noise exposure benefit from hearing-conservation counseling and hearing protection as both a prevention and a secondary-prevention measure once tinnitus has developed — cross-reference the Hearing Loss chapter's prevention content for the full discussion.

Chronic subjective tinnitus

Reassess bothersome tinnitus within a few months of starting any non-pharmacologic therapy (CBT, sound therapy, tinnitus retraining therapy, or hearing aid amplification) — confirm adherence and re-administer a validated tool such as the Tinnitus Handicap Inventory to track functional impact over time rather than relying on an unstructured "is it better?" question alone.^[3] Reassess mood and sleep at the same visits, given how closely these track with perceived tinnitus severity (see Special Populations).

Ototoxic drug-induced tinnitus

Systematically ask about tinnitus, subjective hearing change, aural fullness, and dizziness at every clinical contact during a course of a known ototoxic agent — this is a genuinely practical, low-cost complement to formal audiometry, and the pharmacist's specific role is flagging this opportunity and escalating any positive finding promptly rather than assuming someone else will catch it.^[3] See the Hearing Loss chapter for the full baseline-and-serial audiometry protocol and timing benchmarks, which this chapter deliberately does not repeat.

Pulsatile tinnitus with an identified structural or vascular cause

Follow-up is directed by the managing specialist (neurotology, neurosurgery, or interventional neuroradiology) per the lesion-specific protocol; the pharmacist's role is supporting medication management around any procedural intervention and reinforcing why the imaging work-up and any subsequent procedure were genuinely necessary, not incidental.

When to re-image or re-refer

A change in tinnitus character (new pulsatility, new asymmetry, or a shift from bilateral to unilateral), progressive or asymmetric hearing loss, or a persistent complaint despite an initially normal work-up are all reasons to revisit the diagnosis rather than assume the original classification still holds — see Treatment Failure/Next Step.

1. Bothersome subjective tinnitus not meaningfully improved after an adequate trial of CBT and/or sound therapy: reassess adherence, add tinnitus retraining therapy if not already tried, and formally screen (or re-screen) for comorbid depression, anxiety, and sleep disturbance if not already addressed directly.
2. Pulsatile tinnitus with a normal initial MRI/MRA/MRV: reassess for a mechanical (pseudo-pulsatile) cause such as palatal or tensor tympani/stapedius myoclonus; if suspicion for a vascular lesion genuinely remains, escalate imaging to CT angiography or refer for digital subtraction angiography rather than assuming the negative study is final.
3. Unilateral tinnitus or asymmetric hearing loss with an initially unremarkable work-up: refer (or re-refer) to otolaryngology/audiology, since a vestibular schwannoma or another retrocochlear cause can present subtly and warrants a low threshold for imaging.
4. New tinnitus during a known ototoxic drug course not resolving after prescriber escalation: continue coordinated monitoring per the Hearing Loss chapter's protocol rather than assuming a single dose adjustment has fully addressed the risk.
5. Comorbid depression, anxiety, or insomnia not responding to first-line management: refer to psychiatry or psychology rather than continuing to treat tinnitus in isolation from its genuine mental-health impact.
6. Severe, treatment-refractory tinnitus significantly impacting quality of life or safety, including any suicidal ideation: escalate urgently per the Suicide Risk & Prevention chapter and refer to a multidisciplinary tinnitus or audiology program where available, rather than continuing routine primary-care management alone.

• Not asking specifically whether tinnitus is pulsatile or nonpulsatile, and unilateral or bilateral — missing the single most important branch point in the entire work-up.
• Ordering routine imaging for typical bilateral, nonpulsatile tinnitus with a normal exam — low-value, costly, and not supported by current guidance.
• Missing pulsatile tinnitus as a red flag and not pursuing the specific vascular/structural work-up, rather than treating it as routine subjective tinnitus.
• Treating unilateral tinnitus with a normal otoscopic exam as reassuring on its own, rather than pursuing audiology referral and imaging to exclude a vestibular schwannoma.
• Promising a cure for chronic subjective tinnitus rather than honestly setting expectations around reducing impact.
• Reaching for antidepressants, anticonvulsants, anxiolytics, intratympanic medications, or dietary supplements as tinnitus-specific therapy, rather than reserving pharmacotherapy for a genuinely diagnosed comorbid indication.
• Not screening for or actively addressing comorbid anxiety, depression, or sleep disturbance in a patient with bothersome tinnitus.
• Not asking about ototoxic medication history during the tinnitus work-up, missing an actionable, potentially modifiable cause.
• Dismissing tinnitus reported during a course of a known ototoxic agent as an expected nuisance rather than an early, often still-reversible warning sign warranting prompt escalation.
• Assuming aminoglycoside- and salicylate-induced tinnitus behave the same way — missing the genuinely important reversibility contrast between them.
• Not offering a hearing aid evaluation when comorbid hearing loss is present, even when tinnitus itself is the presenting complaint.
• Managing a patient whose tetrad (tinnitus, episodic vertigo, fluctuating hearing loss, aural fullness) actually fits Ménière's disease as routine isolated tinnitus rather than recognizing the pattern and consulting the dedicated chapter.

How to use this table: doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page. No agent in this table cures tinnitus itself — the first table identifies genuine ototoxic culprits to recognize and escalate, the second addresses genuine comorbid targets, and the third states plainly what current guidance advises against.

Ototoxic Drug Culprits — Tinnitus as the Earliest Warning Sign

This chapter's centerpiece table. Tinnitus is very often the earliest, most practical bedside sign of ototoxicity from these agents — frequently reported before any change is measurable on formal audiometry. Reversibility genuinely differs by agent; the aminoglycoside-versus-salicylate contrast below is a useful teaching point in its own right.

Adjunct Pharmacotherapy for Comorbid Symptoms — Not Tinnitus-Specific Therapy

No drug is Health Canada- or FDA-approved specifically to treat tinnitus. The agents below address a genuine comorbid target (sleep, a diagnosed mood disorder) rather than the tinnitus percept itself, and should be presented to patients that way.

What Current Guidance Recommends Against for Primary Tinnitus

Included here explicitly, with no slug/link, because these are recommendations against a class of use rather than a specific product to verify — each carries its own class-specific adverse-effect burden with no offsetting tinnitus-specific benefit.